Media Teleconference: FDA Approves Alli(TM) (Orlistat 60 Mg Capsules) Over-the-Counter
February 8, 2007
PITTSBURGH, Feb. 8 /PRNewswire/ —
WHAT: Today, the U.S. Food and Drug Administration (FDA) approved the weight-loss product orlistat 60 mg capsules for over-the-counter (OTC) use in the United States. Marketed under the brand name alli(TM), this is the only FDA-approved weight-loss product soon to be available without a prescription and the first clinically- proven OTC product to be combined with a comprehensive support program. It is for use by overweight adults in conjunction with a reduced-calorie, low-fat diet. Please join us for a teleconference, where you will learn more about alli, a truly unique approach to weight loss that combines a safe and effective product with an innovative, personalized support program. There will also be a question and answer session. WHO: George Quesnelle, President, North America, GlaxoSmithKline Consumer Healthcare Steve Burton, Vice President, Weight Control Division, GlaxoSmithKline Consumer Healthcare Dr. Vidhu Bansal, Pharm. D, Director of Medical Affairs, GlaxoSmithKline Consumer Healthcare Caroline Apovian, MD, Director of the Center for Nutrition and Weight Management, Boston Medical Center One-on-one interviews are available upon request WHY: Consumers spend billions of dollars each year on fad diets, unproven weight-loss miracle pills and potentially unsafe supplements that may not work. Approximately 65 percent of U.S. adults are overweight or obese, according to the National Institutes of Health. Overweight and obesity are associated with an increased risk of developing hypertension, type 2 diabetes and heart disease. WHEN: Thursday, February 8, 2007 10:30 a.m. – 11:30 a.m. ET DIAL-IN: Please use the following dial-in information to participate: Dial-in #: (800) 374-2482 Conference ID #: 8026958[For International Participants, Dial: (706) 679-5684]
Dr. Apovian has provided medical expertise and advice throughout the development of the alli program and has received compensation for her time to do so.
GlaxoSmithKline Consumer Healthcare
CONTACT: Dave Schemelia, HealthSTAR Public Relations, +1-646-722-8819(Office), or +1-609-468-9325 (Cell), for GlaxoSmithKline Consumer Healthcare